Boehringer and Eli Lilly meet primary endpoints in heart failure treatment studies
In a new phase III trial, Boehringer Ingelheim and Eli Lilly have received positive results with the diabetes drug Jardiance for treating chronic heart failure.
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT
Boehringer Ingelheim and Eli Lilly have received breakthrough results in their Empreror-Preserved phase III study of type 2 diabetes drug Jardiance. It is the first succesful treatment for chronic heart failure, or a weak pulse with preserved ejection fraction.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly welcomes competition for cheap insulin in US
For subscribers
